Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $2.26 billion. The enterprise value is $1.62 billion.
| Market Cap | 2.26B |
| Enterprise Value | 1.62B |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 78.55 million shares outstanding. The number of shares has increased by 9.04% in one year.
| Current Share Class | 78.55M |
| Shares Outstanding | 78.55M |
| Shares Change (YoY) | +9.04% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 111.73% |
| Float | 73.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14,331.99 |
| Forward PS | 999.26 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 3.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10,278.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.97, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.97 |
| Quick Ratio | 10.75 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.54% and return on invested capital (ROIC) is -33.17%.
| Return on Equity (ROE) | -49.54% |
| Return on Assets (ROA) | -30.52% |
| Return on Invested Capital (ROIC) | -33.17% |
| Return on Capital Employed (ROCE) | -50.60% |
| Weighted Average Cost of Capital (WACC) | 9.85% |
| Revenue Per Employee | $798 |
| Profits Per Employee | -$1.56M |
| Employee Count | 198 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.89% in the last 52 weeks. The beta is 1.03, so CLDX's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +18.89% |
| 50-Day Moving Average | 31.98 |
| 200-Day Moving Average | 32.84 |
| Relative Strength Index (RSI) | 43.46 |
| Average Volume (20 Days) | 959,026 |
Short Selling Information
The latest short interest is 9.60 million, so 12.22% of the outstanding shares have been sold short.
| Short Interest | 9.60M |
| Short Previous Month | 11.01M |
| Short % of Shares Out | 12.22% |
| Short % of Float | 13.14% |
| Short Ratio (days to cover) | 4.27 |
Income Statement
In the last 12 months, CLDX had revenue of $158,000 and -$309.06 million in losses. Loss per share was -$4.27.
| Revenue | 158,000 |
| Gross Profit | -283.13M |
| Operating Income | -334.46M |
| Pretax Income | -309.06M |
| Net Income | -309.06M |
| EBITDA | -330.73M |
| EBIT | -334.46M |
| Loss Per Share | -$4.27 |
Balance Sheet
The company has $650.32 million in cash and $9.87 million in debt, with a net cash position of $640.45 million or $8.15 per share.
| Cash & Cash Equivalents | 650.32M |
| Total Debt | 9.87M |
| Net Cash | 640.45M |
| Net Cash Per Share | $8.15 |
| Equity (Book Value) | 649.47M |
| Book Value Per Share | 8.27 |
| Working Capital | 603.22M |
Cash Flow
In the last 12 months, operating cash flow was -$251.97 million and capital expenditures -$7.77 million, giving a free cash flow of -$259.74 million.
| Operating Cash Flow | -251.97M |
| Capital Expenditures | -7.77M |
| Depreciation & Amortization | 3.73M |
| Net Borrowing | n/a |
| Free Cash Flow | -259.74M |
| FCF Per Share | -$3.31 |
Margins
| Gross Margin | n/a |
| Operating Margin | -211,684.81% |
| Pretax Margin | -195,608.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.04% |
| Shareholder Yield | -9.04% |
| Earnings Yield | -14.81% |
| FCF Yield | -11.47% |
Analyst Forecast
The average price target for CLDX is $64.00, which is 121.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $64.00 |
| Price Target Difference | 121.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 309.12% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
CLDX has an Altman Z-Score of 14.47 and a Piotroski F-Score of 1.
| Altman Z-Score | 14.47 |
| Piotroski F-Score | 1 |